These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial. Staehler M; Stöckle M; Christoph DC; Stenzl A; Potthoff K; Grimm MO; Klein D; Harde J; Brüning F; Goebell PJ; Augustin M; Roos F; Benz-Rüd I; Marschner N; Grünwald V Int J Cancer; 2021 Apr; 148(7):1685-1694. PubMed ID: 33070307 [TBL] [Abstract][Full Text] [Related]
31. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study. Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478 [TBL] [Abstract][Full Text] [Related]
32. Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. Nakaigawa N; Tomita Y; Tamada S; Tatsugami K; Osawa T; Oya M; Kanayama H; Miura Y; Sassa N; Nishimura K; Nozawa M; Masumori N; Miyoshi Y; Kuroda S; Kimura A Int J Clin Oncol; 2023 Mar; 28(3):416-426. PubMed ID: 36595123 [TBL] [Abstract][Full Text] [Related]
33. [Cabozantinib: Mechanism of action, efficacy and indications]. Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875 [TBL] [Abstract][Full Text] [Related]
34. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G Clin Genitourin Cancer; 2019 Aug; 17(4):291-298. PubMed ID: 31178240 [TBL] [Abstract][Full Text] [Related]
35. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Bracarda S; Hutson TE; Porta C; Figlin RA; Calvo E; Grünwald V; Ravaud A; Motzer R; Kim D; Anak O; Panneerselvam A; Escudier B Br J Cancer; 2012 Apr; 106(9):1475-80. PubMed ID: 22441644 [TBL] [Abstract][Full Text] [Related]
36. Cabozantinib use in renal cell carcinoma. Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002 [TBL] [Abstract][Full Text] [Related]
37. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan. Chandler C; Burnett H; Schaible K; Senthil V; Kato M; Miura Y; Osawa T; Uemura H; Kuwabara H J Med Econ; 2023; 26(1):1009-1018. PubMed ID: 37505931 [TBL] [Abstract][Full Text] [Related]
39. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551 [TBL] [Abstract][Full Text] [Related]
40. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]